These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
98 related articles for article (PubMed ID: 1962908)
1. Effect of low molecular weight heparin preparations on the inhibition of thrombin by heparin cofactor II. Tollefsen DM; Sugimori T; Maimone MM Semin Thromb Hemost; 1990 Oct; 16 Suppl():66-70. PubMed ID: 1962908 [TBL] [Abstract][Full Text] [Related]
2. Comparative studies of heparin cofactor activity toward antithrombin III and heparin cofactor II, and antithrombin III affinity between low molecular weight heparin and unfractionated heparin. Shimotori T; Sakuragawa N Semin Thromb Hemost; 1990 Oct; 16 Suppl():71-6. PubMed ID: 1962909 [TBL] [Abstract][Full Text] [Related]
3. Antithrombin III- and heparin cofactor II-mediated anticoagulant and antiprotease actions of heparin and its synthetic analogues. Jeske W; Fareed J Semin Thromb Hemost; 1993; 19 Suppl 1():241-7. PubMed ID: 8362268 [TBL] [Abstract][Full Text] [Related]
4. Inhibition of thrombin by antithrombin III and heparin cofactor II in vivo. Liu L; Dewar L; Song Y; Kulczycky M; Blajchman MA; Fenton JW; Andrew M; Delorme M; Ginsberg J; Preissner KT Thromb Haemost; 1995 Mar; 73(3):405-12. PubMed ID: 7545318 [TBL] [Abstract][Full Text] [Related]
5. An approach to assigning in vitro potency to unfractionated and low molecular weight heparins based on the inhibition of prothrombin activation and catalysis of thrombin inhibition. Ofosu FA; Smith LM; Anvari N; Blajchman MA Thromb Haemost; 1988 Oct; 60(2):193-8. PubMed ID: 2851191 [TBL] [Abstract][Full Text] [Related]
6. An algal sulfated galactan has an unusual dual effect on venous thrombosis due to activation of factor XII and inhibition of the coagulation proteases. Melo FR; Mourão PA Thromb Haemost; 2008 Mar; 99(3):531-8. PubMed ID: 18327401 [TBL] [Abstract][Full Text] [Related]
7. Thrombin-based antithrombin assays show overestimation of antithrombin III activity in patients on heparin therapy due to heparin cofactor II influence. Bohner J; von Pape KW; Blaurock M Thromb Haemost; 1994 Mar; 71(3):280-3. PubMed ID: 8029789 [TBL] [Abstract][Full Text] [Related]
8. Fibrin moderates the catalytic action of heparin but not that of dermatan sulfate on thrombin inhibition in human plasma. Okwusidi JI; Anvari N; Kulczycky M; Blajchman MA; Buchanan MR; Ofosu FA J Lab Clin Med; 1991 May; 117(5):359-64. PubMed ID: 2019790 [TBL] [Abstract][Full Text] [Related]
9. Studies on the structural requirements of heparin for the catalysis of thrombin inhibition by heparin cofactor II. Sié P; Petitou M; Lormeau JC; Dupouy D; Boneu B; Choay J Biochim Biophys Acta; 1988 Aug; 966(2):188-95. PubMed ID: 3401503 [TBL] [Abstract][Full Text] [Related]
10. Mechanisms for the anticoagulant effect of heparin and related polysaccharides. Ofosu FA Nouv Rev Fr Hematol (1978); 1988; 30(3):155-60. PubMed ID: 2971155 [TBL] [Abstract][Full Text] [Related]
11. Comparative inhibition of extrinsic and intrinsic thrombin generation by standard heparin, a low molecular weight heparin and the synthetic ATIII-binding pentasaccharide. Lormeau JC; Herault JP Thromb Haemost; 1993 Feb; 69(2):152-6, 176. PubMed ID: 8384381 [TBL] [Abstract][Full Text] [Related]
12. The effects of human thrombomodulin on the inactivation of thrombin by its serum inhibitors. Thompson EA; Salem HH Thromb Haemost; 1987 Oct; 58(3):806-10. PubMed ID: 2829375 [TBL] [Abstract][Full Text] [Related]
13. [The antithrombin action of stichopus japonicus acid mucopolysaccharide (Sjamp) is mediated by heparin cofactor II]. Zhang G Zhonghua Xue Ye Xue Za Zhi; 1997 Mar; 18(3):126-9. PubMed ID: 15622771 [TBL] [Abstract][Full Text] [Related]
14. Pharmacologic modulation of thrombin generation associated with human clots by human purified antithrombin alone or in the presence of low molecular weight heparin or unfractionated heparin. Meddahi S; Bara L; Fessi H; Samama MM Blood Coagul Fibrinolysis; 2000 Jan; 11(1):51-9. PubMed ID: 10691099 [TBL] [Abstract][Full Text] [Related]
15. Antithrombin III and heparin cofactor II in patients with chronic renal failure undergoing regular hemodialysis. Toulon P; Jacquot C; Capron L; Frydman MO; Vignon D; Aiach M Thromb Haemost; 1987 Jun; 57(3):263-8. PubMed ID: 3660328 [TBL] [Abstract][Full Text] [Related]
16. Dermatan sulfate is a more potent inhibitor of clot-bound thrombin than unfractionated and low molecular weight heparins. Bendayan P; Boccalon H; Dupouy D; Boneu B Thromb Haemost; 1994 May; 71(5):576-80. PubMed ID: 8091383 [TBL] [Abstract][Full Text] [Related]
17. Mechanism of potentiation of antithrombin III and heparin cofactor II inhibition by sulfated xylans. Carson L; Doctor VM Thromb Res; 1990 May; 58(4):367-81. PubMed ID: 1972302 [TBL] [Abstract][Full Text] [Related]
18. Ligand binding to thrombin exosite II induces dissociation of the thrombin-heparin cofactor II(L444R) complex. Han JH; Tollefsen DM Biochemistry; 1998 Mar; 37(9):3203-9. PubMed ID: 9485475 [TBL] [Abstract][Full Text] [Related]
19. [Effect of heparin cofactor II on the antithrombin III activities measured by thrombin methods or factor Xa methods--fundamental studies and clinical studies using the plasma of pregnant women]. Akai Y; Shiga S; Tohyama K; Shimatsu A; Ichiyama S Rinsho Byori; 2000 Sep; 48(9):867-71. PubMed ID: 11051806 [TBL] [Abstract][Full Text] [Related]
20. The influence of molecular weight on the biological activity of heparin like sulphated hyaluronic acids. Barbucci R; Lamponi S; Magnani A; Renier D Biomaterials; 1998; 19(7-9):801-6. PubMed ID: 9663756 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]